Brain metastases in patients with renal cell cancer receiving new targeted treatment

Journal of Clinical Oncology

Volumn 26, Issue 1, 2008, Pages 152-154

  Helgason, Helgi H ^a   Mallo, Henk A ^a   Droogendijk, Helga ^a   Haanen, John G ^a   Van Der Veldt, Astrid A M ^a   Van Den Eertwegh, Alfonsus J ^a   Boven, Epie ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; DEXAMETHASONE; FLUOROURACIL; INTERLEUKIN 2; INTERLEUKIN 6 ANTIBODY; SUNITINIB;

ADULT; ANAMNESIS; ARTICLE; BRAIN METASTASIS; BRAIN RADIATION; CANCER STAGING; CANCER THERAPY; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; FATIGUE; HUMAN; KIDNEY CARCINOMA; LUNG METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RASH; STOMATITIS; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CARCINOMA, RENAL CELL; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PYRROLES; TREATMENT OUTCOME;

EID: 37849054055     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.13.5814     Document Type: Article

References (14)

1. Tsuchida Y, Therasse P: Response evaluation criteria in solid tumors (RECIST): New guidelines. Med Pediatr Oncol 37:1-3, 2001
2. Faivre S, Delbaldo C, Vera K, et al: Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25-35, 2006
3. Gay PC, Litchy WJ, Cascino TL: Brain metastasis in hypernephroma. J Neurooncol 5:51-56, 1987
4. Hafez KS, Novick AC, Campbell SC: Patterns of tumor recurrence and guidelines for followup after nephron sparing surgery for sporadic renal cell carcinoma. J Urol 157:2067-2070, 1997
5. Ljungberg B, Alamdari FI, Rasmuson T, et al: Follow-up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy. BJU Int 84:405-411, 1999
6. Barnholtz-Sloan JS, Sloan AE, Davis FG, et al: Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 22:2865-2872, 2004
7. Gore ME, Porta C, Oudard S, et al: Sunitinib in metastatic renal cell carcinoma (mRCC): Preliminary assessment of toxicity in an expanded access trial with subpopulation analysis. J Clin Oncol 25:237s, 2007 (suppl; abstr 5010)
8. Schouten LJ, Rutten J, Huveneers HA, et al: Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 94:2698-2705, 2002
9. Wrónski M, Maor MH, Davis BJ, et al: External radiation of brain metastases from renal carcinoma: A retrospective study of 119 patients from the M.D. Anderson Cancer Center. Int J Radiat Oncol Biol Phys 37:753-759, 1997
10. Sheehan JP, Sun MH, Kondziolka D, et al: Radiosurgery in patients with renal cell carcinoma metastasis to the brain: Long-term outcomes and prognostic factors influencing survival and local tumor control. J Neurosurg 98:342-349, 2003
11. Massard C, Zonierek J, Laplanche A, et al: Incidence of brain metastasis in advanced renal cell carcinoma among patients randomized in a phase III trial of sorafenib, an oral multi-kinase inhibitor. Ann Oncol 17:ix146, 2006 (suppl 9; abstr 454P)
12. Patyna S, Peng G: Distribution of sunitinib and its active metabolite in brain and spinal cord tissue following oral or intravenous administration in rodents and monkeys. Eur J Cancer 4:21-22, 2006 (abstr 56)
13. Dai H, Marbach P, Lemaire M, et al: Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J Pharmacol Exp Ther 304:1085-1092, 2003
14. Batchelor TT, Sorensen AG, di Tomaso E, et al: AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83-95, 2007